JP Morgan Maintains Neutral on Quest Diagnostics, Raises Price Target to $155
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Lisa Gill maintains a Neutral rating on Quest Diagnostics (NYSE:DGX) and raises the price target from $152 to $155.

May 30, 2024 | 6:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan analyst Lisa Gill maintains a Neutral rating on Quest Diagnostics and raises the price target from $152 to $155.
The Neutral rating suggests that the analyst does not expect significant short-term movement in the stock price. However, the slight increase in the price target indicates a modestly positive outlook.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100